Genmab — September 2017
-
meanwhile, NICE is not just difficult with Dara ; NICE throws a wrench in Takeda's Ninlaro growth plans with second rejection http://www.fiercepharma.com/pharma/nice-burns-takeda-again-second-ninlaro-rejection
-
CAR-T tourism starting? "... According to a Chinese media report this week, an American patient paid out of his own pocket to go to China to access what is perhaps the most promising technology .." https://www.myeloma.org/blog/dr-duries/university-california-girds-combat-cancer-closer-look-car-t-cell-therapy-and-medical?utm_content=buffer10ca4&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer
-
️
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind